Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
Khaled Musallam, Group Chief Research Officer Burjeel Holdings, Adj. Prof. Khalifa University and Weill Cornell Medicine (NY), shared on LinkedIn:
”Pleased to share results from our de-LIGHT study out now in the British Journal of Haematology. What makes this data special and what’s its added value:
- Most studies evaluating the impact of anemia and iron overload on morbidity and mortality outcomes in beta-thalassemia (including those from our group) used spot indices or followed patients over short or defined periods of time. In de-LIGHT, it took tremendous effort but we were able to capture a lifetime observation since diagnosis looking at anemia/iron vs outcomes over a median follow up of 38 years in 500+ patients
- We defined patients as having NTDT or TDT based on lifetime exposure to transfusions (rather than their status ‘now’ or in the past 6 months)
- We used a lifetime anemia and iron control index (LAICI) defined based on adherence to TIF guidelines recommendations in NTDT and TDT. This was significantly and independently associated with overall survival and incidence of various morbidities.
Thalassemia treatment is lifelong, and evidence-based, optimal management of anemia and iron overload should persist over the entire disease course and cannot be sporadic.”
Read the full article here.
Article: Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study
Authors: Khaled Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone, Antonino Giangreco, Maria Concetta Renda, Emanuela Fecarotta, Antonio Troia, Antonino Giambona, Giovan Battista Ruffo, Efthymia Vlachaki, Theodora M. Venou, Paolo Ricchi, Brunella Ziello, Marilena Serra, Elena Colizzi, Filomena Longo, Martina Culcasi, Aurelio Maggio

Stay updated on the latest scientific advances in the field of hematology with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC